Uproleselan Plus SOC Targeted Regimens and Chemotherapy Under Investigation in AML
Bhavana “Tina” Bhatnagar, DO, discusses the mechanism of action of uproleselan, the potential efficacy and safety benefits of adding this agent to standard therapeutic regimens in patients with AML, and the importance of considering MRD negativity as an end point in AML clinical trials.
United States Bhavana Tina Bhatnagar Danielj Deangelo Oncology At West Virginia University Cancer Institute Department Of Medicine At West Virginia University University Of California
Source: onclive.com